Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society ... - Morningstar
Additional data from SEQUOIA-HCM trial show aficamten improves cardiac remodeling, structure, function, symptoms, and biomarkers in patients with obstructive hypertrophic cardiomyopathy (HCM). Presentations at the European Society of Cardiology Congress 2024 were accompanied by four simultaneous journal publications. Cytokinetics to host a conference call on September 3rd to discuss these findings.
Highlighted Terms
Related News
Additional data from SEQUOIA-HCM trial show aficamten improves cardiac remodeling, structure, function, symptoms, and biomarkers in patients with obstructive hypertrophic cardiomyopathy (HCM). Presentations at the European Society of Cardiology Congress 2024 were accompanied by four simultaneous journal publications. Cytokinetics to host a conference call on September 3rd to discuss these findings.
New data on aficamten's safety and long-term use presented at the European Society of Cardiology Congress 2024, showing it well-tolerated with a profile similar to placebo. Analysis from FOREST-HCM demonstrates successful withdrawal of standard of care medications in patients with obstructive HCM treated with aficamten. Company to host conference call and webcast on September 3rd.